FOUND: 19 - You Need To See This

Eli Lilly's Quarterly Earnings Preview: What You Need to Know

Eli Lilly is scheduled to report its first-quarter results next month, and analysts expect a significant double-digit earnings growth.

Barchart · Apr 22, 2025

Swiss drugmaker Roche to invest $50bn in US in effort to dodge Trump tariffs

Company says it will create 12,000 jobs in manufacturing and R&D over next five years

The Guardian - UK · Apr 22, 2025

Goldman Sachs Just Upgraded This Blue-Chip Stock. Should You Buy It Now?

With a strong pipeline, this pharmaceutical powerhouse is positioning itself as a dominant force in the future of medicine.

Barchart · Apr 18, 2025

Hims’ Weight Loss Expansion: Real Growth or Just Hype?

Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?

MarketBeat · Apr 10, 2025

Experimental Drug Shows Promise In Eliminating Hard-To-Treat Deadly Cholesterol

A single dose of lepodisiran dramatically lowered dangerous lipoprotein(a) levels for up to a year, offering new hope for heart disease treatment.

Medical Daily · Apr 1, 2025

Novo Nordisk shares post the biggest monthly decline since 2002

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several disappointing trial results. However, analysts remain optimistic about the shares, forecasting a potential price upside of up to 60% over the next 12 months.

Euronews · Apr 1, 2025

Who should avoid taking viral drug Mounjaro? Expert explains

Eli Lilly's recent launch of Mounjaro (tirzepatide) in India has sparked significant interest especially among those looking for weight loss and diabetes control.

The Times of India · Mar 30, 2025

European committee says Lilly Alzheimer's drug shouldn't get marketing approval

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling

The Independent UK · Mar 28, 2025

EU regulators block new Alzheimer’s drug citing potentially fatal side effects

The company behind the drug donanemab said it will ask regulators to reconsider the decision.

Euronews · Mar 28, 2025

Tariff treatment: Six diagnoses for EU pharma sector amid US trade war

Potential US tariffs on pharmaceuticals could set off a ripple effect that extends far beyond the immediate price hikes, as both the US and Europe heavily rely on each other.

Euronews · Mar 28, 2025